Zeist, Netherlands, April 22, 2024 â We proudly welcome Stefan Timmerman as our new Chief Financial Officer (CFO), effective April 1st, following up Eelco Brouwer, who played a crucial role in the completion of the Ampersand transaction last yea...
Zeist, Netherlands, April 5, 2024Â â Weâre proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius Clinical The estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024 GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners Partnership will further expand Juliusâ clinical trial services capabilities to advance new therapeutics. Zeist, Netherlands, November 28, 2023 -- Julius Cli...
We are excited to announce that Julius Clinical has a brand-new look and website as part of the ongoing evolution of our companyâs brand. Why? Ever since its foundation in 2008, Julius Clinical has been based on a unique triangle of scientif...
We are proud to announce the publication of our latest research article titled "A global survey of health care workers' awareness of nonâalcoholic fatty liver disease: The AwareNASH survey." This article summarizes the findings of the AwareNASH ...
Last Friday, the results of the CONVINCE trial were published in the prestigious New England Journal of Medicine. We are thrilled to announce that the CONVINCE study has shown that the use of high-dose hemodiafiltration led to a remarkable 23% low...
"*" indicates required fields
"*" indicates required fields
